OCU100 Granted Orphan Drug for Retinitis Pigmentosa
Ocugen announced that OCU100 has received orphan drug status from the DA for the treatment of retinitis pigmentosa (RP). RP refers to a group of rare, inherited ophthalmic diseases where the cells responsible for light sensing within the retina of the eye are damaged or dead.
OCU100 is a recombinant lens epithelium derived growth factor 1-326 (LEDGF1-326) that reduces protein aggregation and associated stresses in retinal cells. Ocugen plans on commencing with a Phase 1 study for safety and tolerability of OCU100 in patients sometime in 2015.
For more information call (720) 859-3549 or visit Ocugen.com.